The fruits of our efforts: time for a different view of lung cancer and CT screening

Frank Detterbeck

Lung cancer continues to be by far the leading cause of cancer deaths, primarily because it is usually not found until it is in a relatively advanced stage. As a result, a great deal of effort has focused on using CT imaging to screen a broad population. The two most influential papers on CT screening for lung cancer published recently have drawn conclusions that are diametrically opposed.1 2 Henschke et al3 found compelling evidence that CT screening would save many patients from death, while Bach et al4 concluded that CT screening may lead to harm through overtreatment of inconsequential lung cancers. It is worth taking a closer look at how two thoughtful groups can arrive at such disparate views.

The paper by Henschke et al3 reported a 5-year survival rate of 86% for patients with lung cancer detected by CT screening. This is dramatically better than the 5-year survival rate of 16% for patients with lung cancer detected by routine care and reported through the US national cancer database.5 The implication is that CT screening has changed the outcome of the patients by early detection and early initiation of treatment.

The paper by Bach et al4 compared the results of three single-arm CT screening studies with predicted results using a model derived from and validated in patients with lung cancer detected during routine care as it exists currently. The number of lung cancers and lung cancer resections that actually occurred in the CT screened cohort was much higher than what was predicted by the model, whereas the number of deaths from lung cancer matched closely. The authors therefore concluded that CT screening resulted in overdiagnosis and overtreatment of indolent lung cancers that are of no clinical consequence in a substantial proportion of patients without any benefit.6

Some of the discussion of these papers centred around funding sources and whether there was potential for a bias as a result.4 6 The real issue, however, is to understand why the data from these two studies seem so dissimilar.

An emerging concept is that lung cancer involves a spectrum of tumours ranging from some that are very aggressive to others that are very indolent.2 5 Importantly, it is becoming clear that CT screening in particular selects a population of patients that has a different spectrum of disease than that of patients detected by routine care. For example, a systematic review showed that the average volume doubling time of lung cancers detected during routine care was approximately 135 days compared with almost 500 days for lung cancers detected by CT screening.7 The proportion of patients with long doubling times (>400 days) increased from 3% in patients detected by routine care to 27% in those detected by CT screening.8 10 Thus, a comparison of lung cancers detected by CT screening with those detected by routine care is like comparing apples with oranges.

The comparison inherent in the paper by Henschke et al3 between lung cancers detected by CT screening and those detected during routine care is therefore flawed if the spectrum of disease is different in these two cohorts. Metaphorically, it is inappropriate to conclude from the observed differences that CT screening converted apples into oranges. Instead, one should conclude...
th that the process of CT screening identified many oranges instead of the apples we were accustomed to.

Bach et al recognise that cohorts detected by CT screening are different from those detected by routine care, but applied the same management to both groups. This is somewhat like recognising that oranges are different from apples but using a recipe for apple pie for both. Using this approach leads to the observation that apple pie made with oranges is not desirable.

The underlying problem in the study by Henschke et al lies in viewing lung cancer in a black and white manner; any lung cancer is rapidly fatal. Henschke et al do report that the eight patients diagnosed with lung cancer via CT screening who were not treated died, although no details about these patients are provided (such as cause of death).1 This is consistent with the natural history of lung cancer detected by routine care (5-year survival of 2% for untreated patients with stage I lung cancer).2 However, the black and white view of lung cancer is countered by the consistent finding that there is a spectrum of doubling times among lung cancers, and that this spectrum is markedly shifted to a higher proportion of patients with very long doubling times in tumours detected by CT screening compared with those detected by routine care.3

The paper by Bach et al suffers from a similar black and white manner of thinking: a lung cancer is either a serious disease (requiring the “standard” recipe of treatment) or it is overdiagnosed (and overtreated if the standard approach is used). Much attention has been focused on overdiagnosis bias, meaning patients who are diagnosed with an indolent tumour that has no effect on their length of life (ie, they will die of other causes and not the cancer). Much less attention has been paid to length bias, which occurs when the process of screening selects a higher proportion of patients with less aggressive cancers. A factor contributing to this may be that the term “length bias” is less intuitive and less well understood than lead time bias or overdiagnosis bias. A more intuitive term for length bias may be “spectrum bias”. Nevertheless, death and therefore also mortality of patients with lung cancer remains an unassailable endpoint, making overdiagnosis an issue that cannot be easily brushed aside.

As in most conflicts, it may be that, in some ways, Henschke et al and Bach et al are both right and in some ways they are both wrong. The difficulty in defining the role of CT screening may arise because we are not formulating the questions appropriately. Perhaps it is time to view lung cancer in a more nuanced fashion as a disease that has a wide spectrum of behaviour. If the spectrum of disease is varied, perhaps the treatment should also be varied (ie, sublobar resection, radiofrequency ablation, stereotactic radiosurgery or simply careful observation with subsequent intervention if needed). Perhaps the outcome measures also need to be reassessed (eg, 5-year survival may not be an appropriate measure for indolent tumours).

At present our ability to predict the behaviour of lung cancers is limited, and therefore so is our ability to clearly define new treatment approaches and outcome measures. Nevertheless, it appears that the time has come to address these questions, paying careful attention to the characteristics of the patients involved. The spectrum of disease may be changing not only in CT screening programmes but also in the general population due to an increased prevalence of CT scanning in general.4 A binary black and white view of the biological behaviour and the approach to treatment of lung cancer may be inhibiting us from a full understanding of how best to approach patients and how a high prevalence of CT scanning affects this.

Competing interests: None.


REFERENCES

The fruits of our efforts: time for a different view of lung cancer and CT screening

Frank Detterbeck

Thorax 2009 64: 465-466
doi: 10.1136/thx.2008.106328

Updated information and services can be found at: http://thorax.bmj.com/content/64/6/465

These include:

References
This article cites 11 articles, 2 of which you can access for free at: http://thorax.bmj.com/content/64/6/465#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)
- Screening (oncology) (407)
- Screening (epidemiology) (366)
- Screening (public health) (366)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/